Surfbird Money

Acquisition · Shareholders have voted

Bio-techne Corp acquisition by Merck KGaA, Darmstadt, Germany: what happens to stock options and RSUs

Merck KGaA, Darmstadt, Germany, is buying Bio-Techne for $73.00 per share in cash; shareholders voted on September 23, 2026. Vested options are paid the difference between $73.00 and their exercise price. Check the proxy for unvested options and RSUs.

Buyer
Merck KGaA, Darmstadt, Germany
What holders receive
$73.00 per share in cash
Agreement signed
June 25, 2026
Shareholder vote
September 23, 2026
Expected closing
Not stated in the filing

How equity awards are treated

Stock optionsVested options cashed out for the spread over $73.00; see the proxy for unvested options
Options priced above the dealcancelled for no payment (likely)
Unvested RSUsconverted, keep vesting on original schedule (likely)
Performance awards (PSUs)mentioned; terms vary

Estimate your payout at $73.00 per share

Options pay the spread between the deal price and the exercise price; options priced at or above $73.00 usually pay nothing. Whether unvested awards pay now or later depends on the treatment above. Before taxes.

What this means for your taxes

  • Shares you own outright are sold for cash at closing. That is a taxable sale: the gain over your cost basis is a capital gain, long-term if you have held the shares more than a year at closing. For shares from vested RSUs, your basis is generally the value already taxed at vesting (it was on your W-2).
  • Options and RSUs paid in cash run through payroll as wages: income tax plus Social Security and Medicare. Employers usually withhold federal income tax at a flat 22%, or 37% on supplemental wages above $1 million in the calendar year (IRS Publication 15). If your top bracket is higher than 22%, withholding can fall short and you may owe more when you file; an estimated payment avoids a surprise.
  • Incentive stock options that are cancelled for cash generally do not get ISO treatment: the payment is taxed like wages, the same as non-qualified options.
  • ESPP shares sold in the deal within 2 years of the offering date or 1 year of purchase are a disqualifying disposition: part of the gain is taxed as ordinary income.

General rules, not advice for your situation. Your award agreement and the merger agreement control. Full guide: stock options and RSUs in an acquisition →

Source

From the company's SEC filing: DEFM14A (accession 0001140361-26-033911). Last checked against the filing on November 19, 2026. Found an error? Corrections are made the same day; see how we check.

Questions

What will Bio-techne Corp shareholders receive?

Under the merger agreement, holders receive $73.00 per share in cash.

What happens to Bio-techne Corp stock options and RSUs?

Stock options: Vested options cashed out for the spread over $73.00; see the proxy for unvested options; Options priced above the deal: cancelled for no payment (likely); Unvested RSUs: converted, keep vesting on original schedule (likely); Performance awards (PSUs): mentioned; terms vary

When will the deal close?

The filing does not give a specific closing date; closing depends on approvals.